nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—P-Glycoprotein Inhibitors—Cyclosporine—psoriasis	0.712	1	CiPCiCtD
Bosutinib—BMP2K—synovial membrane of synovial joint—psoriasis	0.00261	0.0548	CbGeAlD
Bosutinib—PTK2—skin epidermis—psoriasis	0.00149	0.0313	CbGeAlD
Bosutinib—CYP3A4—Calcitriol—psoriasis	0.00111	0.103	CbGbCtD
Bosutinib—TLK1—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.0011	0.32	CbGdCrCtD
Bosutinib—PTK2—endothelium—psoriasis	0.00108	0.0227	CbGeAlD
Bosutinib—Vandetanib—VEGFA—psoriasis	0.00103	1	CrCbGaD
Bosutinib—EPHB4—endothelium—psoriasis	0.000983	0.0207	CbGeAlD
Bosutinib—BMX—skin of body—psoriasis	0.000892	0.0187	CbGeAlD
Bosutinib—CYP3A4—Methoxsalen—psoriasis	0.000859	0.0804	CbGbCtD
Bosutinib—SRC—endothelium—psoriasis	0.000836	0.0176	CbGeAlD
Bosutinib—ABCB1—Mycophenolate mofetil—psoriasis	0.000824	0.0771	CbGbCtD
Bosutinib—CDK2—skin of body—psoriasis	0.000812	0.0171	CbGeAlD
Bosutinib—TLK1—tendon—psoriasis	0.000734	0.0154	CbGeAlD
Bosutinib—PRKCQ—tendon—psoriasis	0.000724	0.0152	CbGeAlD
Bosutinib—PLK2—skin of body—psoriasis	0.000716	0.015	CbGeAlD
Bosutinib—ABCB1—Betamethasone—psoriasis	0.000707	0.0662	CbGbCtD
Bosutinib—ABCB1—Prednisolone—psoriasis	0.000697	0.0653	CbGbCtD
Bosutinib—CLK3—tendon—psoriasis	0.000679	0.0143	CbGeAlD
Bosutinib—STK24—skin of body—psoriasis	0.000668	0.014	CbGeAlD
Bosutinib—PHKG1—tendon—psoriasis	0.000664	0.0139	CbGeAlD
Bosutinib—ABCB1—Hydrocortisone—psoriasis	0.000661	0.0619	CbGbCtD
Bosutinib—ABCB1—Prednisone—psoriasis	0.000659	0.0616	CbGbCtD
Bosutinib—EIF2AK1—tendon—psoriasis	0.000657	0.0138	CbGeAlD
Bosutinib—TYRO3—skin of body—psoriasis	0.000647	0.0136	CbGeAlD
Bosutinib—VRK2—tendon—psoriasis	0.000636	0.0134	CbGeAlD
Bosutinib—FES—tendon—psoriasis	0.000636	0.0134	CbGeAlD
Bosutinib—ABCB1—Cyclosporine—psoriasis	0.000624	0.0584	CbGbCtD
Bosutinib—SYK—tendon—psoriasis	0.000624	0.0131	CbGeAlD
Bosutinib—TNIK—tendon—psoriasis	0.000624	0.0131	CbGeAlD
Bosutinib—CDK2—tendon—psoriasis	0.000618	0.013	CbGeAlD
Bosutinib—STK26—tendon—psoriasis	0.000613	0.0129	CbGeAlD
Bosutinib—CHEK2—tendon—psoriasis	0.000592	0.0124	CbGeAlD
Bosutinib—DMPK—tendon—psoriasis	0.000587	0.0123	CbGeAlD
Bosutinib—WEE1—tendon—psoriasis	0.000587	0.0123	CbGeAlD
Bosutinib—BMPR2—skin of body—psoriasis	0.00058	0.0122	CbGeAlD
Bosutinib—CYP3A4—Cholecalciferol—psoriasis	0.000569	0.0533	CbGbCtD
Bosutinib—STK25—tendon—psoriasis	0.00056	0.0118	CbGeAlD
Bosutinib—PLK2—tendon—psoriasis	0.000545	0.0114	CbGeAlD
Bosutinib—SIK3—tendon—psoriasis	0.000541	0.0114	CbGeAlD
Bosutinib—MAP2K1—skin of body—psoriasis	0.000539	0.0113	CbGeAlD
Bosutinib—STK35—skin of body—psoriasis	0.000539	0.0113	CbGeAlD
Bosutinib—CSK—skin of body—psoriasis	0.000535	0.0112	CbGeAlD
Bosutinib—CSNK1A1—skin of body—psoriasis	0.000532	0.0112	CbGeAlD
Bosutinib—CAMK1D—tendon—psoriasis	0.000515	0.0108	CbGeAlD
Bosutinib—STK24—tendon—psoriasis	0.000509	0.0107	CbGeAlD
Bosutinib—CYP3A4—Triamcinolone—psoriasis	0.000494	0.0462	CbGbCtD
Bosutinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.000494	0.0462	CbGbCtD
Bosutinib—CSNK1E—skin of body—psoriasis	0.000493	0.0104	CbGeAlD
Bosutinib—FER—tendon—psoriasis	0.000492	0.0103	CbGeAlD
Bosutinib—SIK1—skin of body—psoriasis	0.000485	0.0102	CbGeAlD
Bosutinib—MAP4K1—tendon—psoriasis	0.000482	0.0101	CbGeAlD
Bosutinib—BTK—tendon—psoriasis	0.00048	0.0101	CbGeAlD
Bosutinib—ERBB3—skin of body—psoriasis	0.000475	0.00999	CbGeAlD
Bosutinib—MAP2K2—skin of body—psoriasis	0.000474	0.00997	CbGeAlD
Bosutinib—MAP4K2—tendon—psoriasis	0.000466	0.0098	CbGeAlD
Bosutinib—PTK2—skin of body—psoriasis	0.000461	0.00969	CbGeAlD
Bosutinib—ERBB4—tendon—psoriasis	0.00046	0.00967	CbGeAlD
Bosutinib—STK3—tendon—psoriasis	0.00046	0.00967	CbGeAlD
Bosutinib—STK25—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000458	0.133	CbGdCrCtD
Bosutinib—BMPR2—tendon—psoriasis	0.000441	0.00927	CbGeAlD
Bosutinib—AXL—skin of body—psoriasis	0.000439	0.00923	CbGeAlD
Bosutinib—STK36—tendon—psoriasis	0.000438	0.0092	CbGeAlD
Bosutinib—MERTK—tendon—psoriasis	0.000433	0.00909	CbGeAlD
Bosutinib—MAP4K4—tendon—psoriasis	0.000425	0.00892	CbGeAlD
Bosutinib—CYP3A4—Betamethasone—psoriasis	0.000423	0.0396	CbGbCtD
Bosutinib—BCR—tendon—psoriasis	0.000422	0.00886	CbGeAlD
Bosutinib—MAP3K12—tendon—psoriasis	0.000419	0.0088	CbGeAlD
Bosutinib—CYP3A4—Prednisolone—psoriasis	0.000418	0.0391	CbGbCtD
Bosutinib—ABCB1—Dexamethasone—psoriasis	0.000411	0.0385	CbGbCtD
Bosutinib—FYN—skin of body—psoriasis	0.000411	0.00864	CbGeAlD
Bosutinib—STK35—tendon—psoriasis	0.00041	0.00862	CbGeAlD
Bosutinib—CASK—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000408	0.118	CbGdCrCtD
Bosutinib—CSK—tendon—psoriasis	0.000407	0.00856	CbGeAlD
Bosutinib—CSNK1A1—tendon—psoriasis	0.000405	0.0085	CbGeAlD
Bosutinib—HCK—tendon—psoriasis	0.000402	0.00845	CbGeAlD
Bosutinib—CLK1—tendon—psoriasis	0.000402	0.00845	CbGeAlD
Bosutinib—MAP3K3—skin of body—psoriasis	0.000402	0.00844	CbGeAlD
Bosutinib—ABL2—tendon—psoriasis	0.0004	0.0084	CbGeAlD
Bosutinib—CYP3A4—Hydrocortisone—psoriasis	0.000396	0.0371	CbGbCtD
Bosutinib—CAMK2G—tendon—psoriasis	0.000395	0.00829	CbGeAlD
Bosutinib—BMP2K—tendon—psoriasis	0.000395	0.00829	CbGeAlD
Bosutinib—CYP3A4—Prednisone—psoriasis	0.000395	0.0369	CbGbCtD
Bosutinib—LRRK2—tendon—psoriasis	0.000391	0.00822	CbGeAlD
Bosutinib—PTK2B—tendon—psoriasis	0.000381	0.00801	CbGeAlD
Bosutinib—CSNK1E—tendon—psoriasis	0.000375	0.00788	CbGeAlD
Bosutinib—CYP3A4—Cyclosporine—psoriasis	0.000374	0.035	CbGbCtD
Bosutinib—SIK1—tendon—psoriasis	0.000369	0.00776	CbGeAlD
Bosutinib—IRAK4—tendon—psoriasis	0.000369	0.00776	CbGeAlD
Bosutinib—EPHA4—tendon—psoriasis	0.000366	0.00768	CbGeAlD
Bosutinib—ULK3—tendon—psoriasis	0.000361	0.00759	CbGeAlD
Bosutinib—MAP2K2—tendon—psoriasis	0.000361	0.00759	CbGeAlD
Bosutinib—SRC—skin of body—psoriasis	0.000357	0.0075	CbGeAlD
Bosutinib—MAP3K7—tendon—psoriasis	0.000355	0.00746	CbGeAlD
Bosutinib—TBK1—tendon—psoriasis	0.000351	0.00738	CbGeAlD
Bosutinib—PTK2—tendon—psoriasis	0.000351	0.00738	CbGeAlD
Bosutinib—IRAK1—tendon—psoriasis	0.000344	0.00723	CbGeAlD
Bosutinib—RPS6KB1—tendon—psoriasis	0.000338	0.0071	CbGeAlD
Bosutinib—FGR—tendon—psoriasis	0.000336	0.00705	CbGeAlD
Bosutinib—AXL—tendon—psoriasis	0.000334	0.00702	CbGeAlD
Bosutinib—ABCB1—Methotrexate—psoriasis	0.00033	0.0309	CbGbCtD
Bosutinib—SLK—tendon—psoriasis	0.000322	0.00676	CbGeAlD
Bosutinib—CSF1R—skin of body—psoriasis	0.00032	0.00673	CbGeAlD
Bosutinib—EPHB4—tendon—psoriasis	0.00032	0.00671	CbGeAlD
Bosutinib—EPHA2—tendon—psoriasis	0.000313	0.00659	CbGeAlD
Bosutinib—FYN—tendon—psoriasis	0.000313	0.00657	CbGeAlD
Bosutinib—MAP4K5—tendon—psoriasis	0.000306	0.00642	CbGeAlD
Bosutinib—MAP3K3—tendon—psoriasis	0.000306	0.00642	CbGeAlD
Bosutinib—PDGFRB—skin of body—psoriasis	0.000284	0.00597	CbGeAlD
Bosutinib—YES1—tendon—psoriasis	0.000282	0.00593	CbGeAlD
Bosutinib—STK10—tendon—psoriasis	0.00028	0.00588	CbGeAlD
Bosutinib—TAOK3—tendon—psoriasis	0.000279	0.00586	CbGeAlD
Bosutinib—ABL1—skin of body—psoriasis	0.000253	0.00532	CbGeAlD
Bosutinib—MAP2K5—tendon—psoriasis	0.00025	0.00525	CbGeAlD
Bosutinib—CYP3A4—Dexamethasone—psoriasis	0.000246	0.0231	CbGbCtD
Bosutinib—CSF1R—tendon—psoriasis	0.000244	0.00512	CbGeAlD
Bosutinib—CSK—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000243	0.0704	CbGdCrCtD
Bosutinib—PDGFRB—tendon—psoriasis	0.000216	0.00454	CbGeAlD
Bosutinib—ABL1—tendon—psoriasis	0.000193	0.00405	CbGeAlD
Bosutinib—EPHB2—Diflorasone—Clobetasol propionate—psoriasis	0.000113	0.0327	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Fluocinonide—psoriasis	9.01e-05	0.0262	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Beclomethasone—psoriasis	9.01e-05	0.0262	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Fluocinolone Acetonide—psoriasis	8.76e-05	0.0254	CbGdCrCtD
Bosutinib—Headache—Hydroxyurea—psoriasis	7.36e-05	0.000799	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—psoriasis	7.35e-05	0.000797	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	7.33e-05	0.000796	CcSEcCtD
Bosutinib—Discomfort—Hydrocortisone—psoriasis	7.29e-05	0.000792	CcSEcCtD
Bosutinib—Connective tissue disorder—Prednisone—psoriasis	7.28e-05	0.00079	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Cyclosporine—psoriasis	7.25e-05	0.000787	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisolone—psoriasis	7.24e-05	0.000786	CcSEcCtD
Bosutinib—Oedema—Prednisolone—psoriasis	7.24e-05	0.000786	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—psoriasis	7.23e-05	0.000785	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—psoriasis	7.19e-05	0.00078	CcSEcCtD
Bosutinib—Cough—Triamcinolone—psoriasis	7.12e-05	0.000773	CcSEcCtD
Bosutinib—Dyspnoea—Cyclosporine—psoriasis	7.1e-05	0.00077	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	7.07e-05	0.000768	CcSEcCtD
Bosutinib—Anaphylactic shock—Hydrocortisone—psoriasis	7.07e-05	0.000768	CcSEcCtD
Bosutinib—Oedema—Hydrocortisone—psoriasis	7.07e-05	0.000768	CcSEcCtD
Bosutinib—Asthenia—Mycophenolic acid—psoriasis	7.06e-05	0.000766	CcSEcCtD
Bosutinib—Infection—Hydrocortisone—psoriasis	7.03e-05	0.000763	CcSEcCtD
Bosutinib—Nausea—Hydroxyurea—psoriasis	6.98e-05	0.000758	CcSEcCtD
Bosutinib—Pruritus—Mycophenolic acid—psoriasis	6.96e-05	0.000756	CcSEcCtD
Bosutinib—Myalgia—Triamcinolone—psoriasis	6.95e-05	0.000754	CcSEcCtD
Bosutinib—Nervous system disorder—Hydrocortisone—psoriasis	6.94e-05	0.000753	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—psoriasis	6.94e-05	0.000753	CcSEcCtD
Bosutinib—Dyspnoea—Mycophenolate mofetil—psoriasis	6.92e-05	0.000752	CcSEcCtD
Bosutinib—Decreased appetite—Cyclosporine—psoriasis	6.92e-05	0.000751	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—psoriasis	6.9e-05	0.000749	CcSEcCtD
Bosutinib—Infestation—Methotrexate—psoriasis	6.9e-05	0.000749	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Cyclosporine—psoriasis	6.87e-05	0.000746	CcSEcCtD
Bosutinib—Skin disorder—Hydrocortisone—psoriasis	6.87e-05	0.000746	CcSEcCtD
Bosutinib—Ill-defined disorder—Dexamethasone—psoriasis	6.87e-05	0.000746	CcSEcCtD
Bosutinib—Ill-defined disorder—Betamethasone—psoriasis	6.87e-05	0.000746	CcSEcCtD
Bosutinib—Discomfort—Triamcinolone—psoriasis	6.86e-05	0.000745	CcSEcCtD
Bosutinib—Fatigue—Cyclosporine—psoriasis	6.86e-05	0.000745	CcSEcCtD
Bosutinib—Pain—Cyclosporine—psoriasis	6.81e-05	0.000739	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—psoriasis	6.78e-05	0.000736	CcSEcCtD
Bosutinib—Decreased appetite—Mycophenolate mofetil—psoriasis	6.75e-05	0.000733	CcSEcCtD
Bosutinib—Diarrhoea—Mycophenolic acid—psoriasis	6.73e-05	0.000731	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	6.7e-05	0.000728	CcSEcCtD
Bosutinib—Immune system disorder—Prednisone—psoriasis	6.69e-05	0.000726	CcSEcCtD
Bosutinib—Malaise—Betamethasone—psoriasis	6.68e-05	0.000725	CcSEcCtD
Bosutinib—Malaise—Dexamethasone—psoriasis	6.68e-05	0.000725	CcSEcCtD
Bosutinib—Oedema—Triamcinolone—psoriasis	6.66e-05	0.000723	CcSEcCtD
Bosutinib—Anaphylactic shock—Triamcinolone—psoriasis	6.66e-05	0.000723	CcSEcCtD
Bosutinib—Pain—Mycophenolate mofetil—psoriasis	6.64e-05	0.000721	CcSEcCtD
Bosutinib—Infection—Triamcinolone—psoriasis	6.62e-05	0.000718	CcSEcCtD
Bosutinib—Feeling abnormal—Cyclosporine—psoriasis	6.56e-05	0.000712	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—psoriasis	6.52e-05	0.000708	CcSEcCtD
Bosutinib—Gastrointestinal pain—Cyclosporine—psoriasis	6.51e-05	0.000707	CcSEcCtD
Bosutinib—Dizziness—Mycophenolic acid—psoriasis	6.51e-05	0.000706	CcSEcCtD
Bosutinib—Malnutrition—Prednisone—psoriasis	6.45e-05	0.0007	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	6.44e-05	0.0007	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—psoriasis	6.44e-05	0.000699	CcSEcCtD
Bosutinib—Feeling abnormal—Mycophenolate mofetil—psoriasis	6.4e-05	0.000695	CcSEcCtD
Bosutinib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.35e-05	0.000689	CcSEcCtD
Bosutinib—Urticaria—Cyclosporine—psoriasis	6.32e-05	0.000686	CcSEcCtD
Bosutinib—Myalgia—Dexamethasone—psoriasis	6.3e-05	0.000684	CcSEcCtD
Bosutinib—Myalgia—Betamethasone—psoriasis	6.3e-05	0.000684	CcSEcCtD
Bosutinib—Abdominal pain—Cyclosporine—psoriasis	6.29e-05	0.000683	CcSEcCtD
Bosutinib—Body temperature increased—Cyclosporine—psoriasis	6.29e-05	0.000683	CcSEcCtD
Bosutinib—Vomiting—Mycophenolic acid—psoriasis	6.26e-05	0.000679	CcSEcCtD
Bosutinib—Discomfort—Betamethasone—psoriasis	6.23e-05	0.000676	CcSEcCtD
Bosutinib—Discomfort—Dexamethasone—psoriasis	6.23e-05	0.000676	CcSEcCtD
Bosutinib—Rash—Mycophenolic acid—psoriasis	6.2e-05	0.000673	CcSEcCtD
Bosutinib—Dermatitis—Mycophenolic acid—psoriasis	6.2e-05	0.000673	CcSEcCtD
Bosutinib—Pain—Prednisolone—psoriasis	6.19e-05	0.000672	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—psoriasis	6.19e-05	0.000672	CcSEcCtD
Bosutinib—Urticaria—Mycophenolate mofetil—psoriasis	6.17e-05	0.00067	CcSEcCtD
Bosutinib—Headache—Mycophenolic acid—psoriasis	6.16e-05	0.000669	CcSEcCtD
Bosutinib—Decreased appetite—Hydrocortisone—psoriasis	6.15e-05	0.000668	CcSEcCtD
Bosutinib—Abdominal pain—Mycophenolate mofetil—psoriasis	6.14e-05	0.000666	CcSEcCtD
Bosutinib—Body temperature increased—Mycophenolate mofetil—psoriasis	6.14e-05	0.000666	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—psoriasis	6.11e-05	0.000664	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	6.11e-05	0.000663	CcSEcCtD
Bosutinib—Fatigue—Hydrocortisone—psoriasis	6.1e-05	0.000662	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—psoriasis	6.07e-05	0.000659	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.07e-05	0.000659	CcSEcCtD
Bosutinib—Pain—Hydrocortisone—psoriasis	6.05e-05	0.000657	CcSEcCtD
Bosutinib—Oedema—Betamethasone—psoriasis	6.04e-05	0.000656	CcSEcCtD
Bosutinib—Anaphylactic shock—Betamethasone—psoriasis	6.04e-05	0.000656	CcSEcCtD
Bosutinib—Oedema—Dexamethasone—psoriasis	6.04e-05	0.000656	CcSEcCtD
Bosutinib—Anaphylactic shock—Dexamethasone—psoriasis	6.04e-05	0.000656	CcSEcCtD
Bosutinib—Infection—Betamethasone—psoriasis	6e-05	0.000652	CcSEcCtD
Bosutinib—Infection—Dexamethasone—psoriasis	6e-05	0.000652	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisone—psoriasis	5.98e-05	0.00065	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisolone—psoriasis	5.97e-05	0.000648	CcSEcCtD
Bosutinib—Anaemia—Prednisone—psoriasis	5.96e-05	0.000647	CcSEcCtD
Bosutinib—Dyspnoea—Triamcinolone—psoriasis	5.94e-05	0.000645	CcSEcCtD
Bosutinib—Nervous system disorder—Betamethasone—psoriasis	5.93e-05	0.000643	CcSEcCtD
Bosutinib—Nervous system disorder—Dexamethasone—psoriasis	5.93e-05	0.000643	CcSEcCtD
Bosutinib—Thrombocytopenia—Betamethasone—psoriasis	5.92e-05	0.000642	CcSEcCtD
Bosutinib—Thrombocytopenia—Dexamethasone—psoriasis	5.92e-05	0.000642	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—psoriasis	5.85e-05	0.000636	CcSEcCtD
Bosutinib—Nausea—Mycophenolic acid—psoriasis	5.84e-05	0.000634	CcSEcCtD
Bosutinib—Feeling abnormal—Hydrocortisone—psoriasis	5.83e-05	0.000633	CcSEcCtD
Bosutinib—Malaise—Prednisone—psoriasis	5.82e-05	0.000631	CcSEcCtD
Bosutinib—Gastrointestinal pain—Hydrocortisone—psoriasis	5.78e-05	0.000628	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—psoriasis	5.77e-05	0.000627	CcSEcCtD
Bosutinib—Urticaria—Prednisolone—psoriasis	5.75e-05	0.000625	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—psoriasis	5.75e-05	0.000624	CcSEcCtD
Bosutinib—Fatigue—Triamcinolone—psoriasis	5.74e-05	0.000623	CcSEcCtD
Bosutinib—Asthenia—Cyclosporine—psoriasis	5.71e-05	0.00062	CcSEcCtD
Bosutinib—Pain—Triamcinolone—psoriasis	5.7e-05	0.000618	CcSEcCtD
Bosutinib—Pruritus—Cyclosporine—psoriasis	5.63e-05	0.000611	CcSEcCtD
Bosutinib—Urticaria—Hydrocortisone—psoriasis	5.62e-05	0.00061	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—psoriasis	5.59e-05	0.000607	CcSEcCtD
Bosutinib—Body temperature increased—Hydrocortisone—psoriasis	5.59e-05	0.000607	CcSEcCtD
Bosutinib—Abdominal pain—Hydrocortisone—psoriasis	5.59e-05	0.000607	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—psoriasis	5.58e-05	0.000606	CcSEcCtD
Bosutinib—Asthenia—Mycophenolate mofetil—psoriasis	5.57e-05	0.000605	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.51e-05	0.000598	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Betamethasone—psoriasis	5.51e-05	0.000598	CcSEcCtD
Bosutinib—Pruritus—Mycophenolate mofetil—psoriasis	5.49e-05	0.000596	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—psoriasis	5.49e-05	0.000596	CcSEcCtD
Bosutinib—Myalgia—Prednisone—psoriasis	5.49e-05	0.000596	CcSEcCtD
Bosutinib—Feeling abnormal—Triamcinolone—psoriasis	5.49e-05	0.000596	CcSEcCtD
Bosutinib—PLK2—Levonorgestrel—Hydrocortisone—psoriasis	5.46e-05	0.0158	CbGdCrCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.45e-05	0.000592	CcSEcCtD
Bosutinib—Diarrhoea—Cyclosporine—psoriasis	5.45e-05	0.000591	CcSEcCtD
Bosutinib—Discomfort—Prednisone—psoriasis	5.42e-05	0.000589	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—psoriasis	5.39e-05	0.000585	CcSEcCtD
Bosutinib—Diarrhoea—Mycophenolate mofetil—psoriasis	5.31e-05	0.000577	CcSEcCtD
Bosutinib—Urticaria—Triamcinolone—psoriasis	5.29e-05	0.000574	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—psoriasis	5.28e-05	0.000573	CcSEcCtD
Bosutinib—Body temperature increased—Triamcinolone—psoriasis	5.27e-05	0.000572	CcSEcCtD
Bosutinib—Dizziness—Cyclosporine—psoriasis	5.26e-05	0.000571	CcSEcCtD
Bosutinib—Oedema—Prednisone—psoriasis	5.26e-05	0.000571	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—psoriasis	5.26e-05	0.000571	CcSEcCtD
Bosutinib—MAP4K4—Testosterone Propionate—Hydrocortisone—psoriasis	5.26e-05	0.0153	CbGdCrCtD
Bosutinib—Decreased appetite—Betamethasone—psoriasis	5.25e-05	0.00057	CcSEcCtD
Bosutinib—Decreased appetite—Dexamethasone—psoriasis	5.25e-05	0.00057	CcSEcCtD
Bosutinib—Infection—Prednisone—psoriasis	5.23e-05	0.000568	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Betamethasone—psoriasis	5.22e-05	0.000566	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Dexamethasone—psoriasis	5.22e-05	0.000566	CcSEcCtD
Bosutinib—Back pain—Methotrexate—psoriasis	5.21e-05	0.000566	CcSEcCtD
Bosutinib—Fatigue—Betamethasone—psoriasis	5.21e-05	0.000566	CcSEcCtD
Bosutinib—Fatigue—Dexamethasone—psoriasis	5.21e-05	0.000566	CcSEcCtD
Bosutinib—Pain—Betamethasone—psoriasis	5.17e-05	0.000561	CcSEcCtD
Bosutinib—Pain—Dexamethasone—psoriasis	5.17e-05	0.000561	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—psoriasis	5.16e-05	0.00056	CcSEcCtD
Bosutinib—Dizziness—Mycophenolate mofetil—psoriasis	5.13e-05	0.000557	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—psoriasis	5.11e-05	0.000555	CcSEcCtD
Bosutinib—Asthenia—Hydrocortisone—psoriasis	5.08e-05	0.000551	CcSEcCtD
Bosutinib—Vomiting—Cyclosporine—psoriasis	5.06e-05	0.000549	CcSEcCtD
Bosutinib—Rash—Cyclosporine—psoriasis	5.02e-05	0.000545	CcSEcCtD
Bosutinib—Dermatitis—Cyclosporine—psoriasis	5.01e-05	0.000544	CcSEcCtD
Bosutinib—Pruritus—Hydrocortisone—psoriasis	5e-05	0.000543	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—psoriasis	5e-05	0.000543	CcSEcCtD
Bosutinib—Headache—Cyclosporine—psoriasis	4.99e-05	0.000541	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—psoriasis	4.98e-05	0.000541	CcSEcCtD
Bosutinib—Feeling abnormal—Dexamethasone—psoriasis	4.98e-05	0.000541	CcSEcCtD
Bosutinib—Feeling abnormal—Betamethasone—psoriasis	4.98e-05	0.000541	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dexamethasone—psoriasis	4.94e-05	0.000537	CcSEcCtD
Bosutinib—Gastrointestinal pain—Betamethasone—psoriasis	4.94e-05	0.000537	CcSEcCtD
Bosutinib—Vomiting—Mycophenolate mofetil—psoriasis	4.94e-05	0.000536	CcSEcCtD
Bosutinib—Rash—Mycophenolate mofetil—psoriasis	4.9e-05	0.000532	CcSEcCtD
Bosutinib—Dermatitis—Mycophenolate mofetil—psoriasis	4.89e-05	0.000531	CcSEcCtD
Bosutinib—Headache—Mycophenolate mofetil—psoriasis	4.86e-05	0.000528	CcSEcCtD
Bosutinib—Malaise—Methotrexate—psoriasis	4.86e-05	0.000528	CcSEcCtD
Bosutinib—Diarrhoea—Hydrocortisone—psoriasis	4.84e-05	0.000525	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—psoriasis	4.82e-05	0.000524	CcSEcCtD
Bosutinib—Urticaria—Dexamethasone—psoriasis	4.8e-05	0.000521	CcSEcCtD
Bosutinib—Urticaria—Betamethasone—psoriasis	4.8e-05	0.000521	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—psoriasis	4.8e-05	0.000521	CcSEcCtD
Bosutinib—Dizziness—Prednisolone—psoriasis	4.79e-05	0.00052	CcSEcCtD
Bosutinib—Asthenia—Triamcinolone—psoriasis	4.78e-05	0.000519	CcSEcCtD
Bosutinib—Body temperature increased—Betamethasone—psoriasis	4.78e-05	0.000519	CcSEcCtD
Bosutinib—Abdominal pain—Betamethasone—psoriasis	4.78e-05	0.000519	CcSEcCtD
Bosutinib—Body temperature increased—Dexamethasone—psoriasis	4.78e-05	0.000519	CcSEcCtD
Bosutinib—Abdominal pain—Dexamethasone—psoriasis	4.78e-05	0.000519	CcSEcCtD
Bosutinib—Nausea—Cyclosporine—psoriasis	4.73e-05	0.000513	CcSEcCtD
Bosutinib—Pruritus—Triamcinolone—psoriasis	4.71e-05	0.000512	CcSEcCtD
Bosutinib—Cough—Methotrexate—psoriasis	4.7e-05	0.000511	CcSEcCtD
Bosutinib—Dizziness—Hydrocortisone—psoriasis	4.68e-05	0.000508	CcSEcCtD
Bosutinib—Nausea—Mycophenolate mofetil—psoriasis	4.61e-05	0.000501	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—psoriasis	4.59e-05	0.000498	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—psoriasis	4.59e-05	0.000498	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—psoriasis	4.59e-05	0.000498	CcSEcCtD
Bosutinib—Decreased appetite—Prednisone—psoriasis	4.58e-05	0.000497	CcSEcCtD
Bosutinib—Rash—Prednisolone—psoriasis	4.57e-05	0.000496	CcSEcCtD
Bosutinib—Dermatitis—Prednisolone—psoriasis	4.56e-05	0.000495	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.56e-05	0.000495	CcSEcCtD
Bosutinib—Fatigue—Prednisone—psoriasis	4.54e-05	0.000493	CcSEcCtD
Bosutinib—Headache—Prednisolone—psoriasis	4.54e-05	0.000493	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—psoriasis	4.53e-05	0.000492	CcSEcCtD
Bosutinib—Vomiting—Hydrocortisone—psoriasis	4.5e-05	0.000488	CcSEcCtD
Bosutinib—Rash—Hydrocortisone—psoriasis	4.46e-05	0.000484	CcSEcCtD
Bosutinib—Dermatitis—Hydrocortisone—psoriasis	4.46e-05	0.000484	CcSEcCtD
Bosutinib—Headache—Hydrocortisone—psoriasis	4.43e-05	0.000481	CcSEcCtD
Bosutinib—Dizziness—Triamcinolone—psoriasis	4.4e-05	0.000478	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—psoriasis	4.4e-05	0.000478	CcSEcCtD
Bosutinib—Infection—Methotrexate—psoriasis	4.37e-05	0.000474	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisone—psoriasis	4.34e-05	0.000471	CcSEcCtD
Bosutinib—Asthenia—Dexamethasone—psoriasis	4.34e-05	0.000471	CcSEcCtD
Bosutinib—Asthenia—Betamethasone—psoriasis	4.34e-05	0.000471	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—psoriasis	4.31e-05	0.000468	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—psoriasis	4.31e-05	0.000468	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—psoriasis	4.3e-05	0.000467	CcSEcCtD
Bosutinib—Nausea—Prednisolone—psoriasis	4.3e-05	0.000467	CcSEcCtD
Bosutinib—Pruritus—Dexamethasone—psoriasis	4.28e-05	0.000464	CcSEcCtD
Bosutinib—Pruritus—Betamethasone—psoriasis	4.28e-05	0.000464	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—psoriasis	4.27e-05	0.000464	CcSEcCtD
Bosutinib—Vomiting—Triamcinolone—psoriasis	4.23e-05	0.00046	CcSEcCtD
Bosutinib—Nausea—Hydrocortisone—psoriasis	4.2e-05	0.000456	CcSEcCtD
Bosutinib—Rash—Triamcinolone—psoriasis	4.2e-05	0.000456	CcSEcCtD
Bosutinib—Dermatitis—Triamcinolone—psoriasis	4.2e-05	0.000456	CcSEcCtD
Bosutinib—Urticaria—Prednisone—psoriasis	4.18e-05	0.000454	CcSEcCtD
Bosutinib—Headache—Triamcinolone—psoriasis	4.17e-05	0.000453	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—psoriasis	4.16e-05	0.000452	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—psoriasis	4.16e-05	0.000452	CcSEcCtD
Bosutinib—Diarrhoea—Dexamethasone—psoriasis	4.14e-05	0.000449	CcSEcCtD
Bosutinib—Diarrhoea—Betamethasone—psoriasis	4.14e-05	0.000449	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Betamethasone—psoriasis	4.11e-05	0.0119	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Dexamethasone—psoriasis	4.11e-05	0.0119	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Triamcinolone—psoriasis	4.01e-05	0.0117	CbGdCrCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—psoriasis	4.01e-05	0.000435	CcSEcCtD
Bosutinib—Dizziness—Dexamethasone—psoriasis	4e-05	0.000434	CcSEcCtD
Bosutinib—Dizziness—Betamethasone—psoriasis	4e-05	0.000434	CcSEcCtD
Bosutinib—Nausea—Triamcinolone—psoriasis	3.96e-05	0.00043	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—psoriasis	3.92e-05	0.000426	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Clobetasol propionate—psoriasis	3.89e-05	0.0113	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Clobetasol propionate—psoriasis	3.89e-05	0.0113	CbGdCrCtD
Bosutinib—Vomiting—Betamethasone—psoriasis	3.84e-05	0.000417	CcSEcCtD
Bosutinib—Vomiting—Dexamethasone—psoriasis	3.84e-05	0.000417	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—psoriasis	3.82e-05	0.000415	CcSEcCtD
Bosutinib—Rash—Betamethasone—psoriasis	3.81e-05	0.000414	CcSEcCtD
Bosutinib—Rash—Dexamethasone—psoriasis	3.81e-05	0.000414	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Prednisone—psoriasis	3.81e-05	0.0111	CbGdCrCtD
Bosutinib—Dermatitis—Betamethasone—psoriasis	3.81e-05	0.000413	CcSEcCtD
Bosutinib—Dermatitis—Dexamethasone—psoriasis	3.81e-05	0.000413	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—psoriasis	3.8e-05	0.000412	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—psoriasis	3.79e-05	0.000412	CcSEcCtD
Bosutinib—Headache—Betamethasone—psoriasis	3.79e-05	0.000411	CcSEcCtD
Bosutinib—Headache—Dexamethasone—psoriasis	3.79e-05	0.000411	CcSEcCtD
Bosutinib—Asthenia—Prednisone—psoriasis	3.78e-05	0.00041	CcSEcCtD
Bosutinib—Pain—Methotrexate—psoriasis	3.76e-05	0.000408	CcSEcCtD
Bosutinib—Pruritus—Prednisone—psoriasis	3.72e-05	0.000404	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Prednisolone—psoriasis	3.72e-05	0.0108	CbGdCrCtD
Bosutinib—Feeling abnormal—Methotrexate—psoriasis	3.62e-05	0.000394	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—psoriasis	3.6e-05	0.000391	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—psoriasis	3.6e-05	0.00039	CcSEcCtD
Bosutinib—Nausea—Dexamethasone—psoriasis	3.59e-05	0.00039	CcSEcCtD
Bosutinib—Nausea—Betamethasone—psoriasis	3.59e-05	0.00039	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—psoriasis	3.49e-05	0.000379	CcSEcCtD
Bosutinib—Dizziness—Prednisone—psoriasis	3.48e-05	0.000378	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—psoriasis	3.48e-05	0.000378	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—psoriasis	3.48e-05	0.000378	CcSEcCtD
Bosutinib—Vomiting—Prednisone—psoriasis	3.35e-05	0.000363	CcSEcCtD
Bosutinib—Rash—Prednisone—psoriasis	3.32e-05	0.00036	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—psoriasis	3.32e-05	0.00036	CcSEcCtD
Bosutinib—Headache—Prednisone—psoriasis	3.3e-05	0.000358	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—psoriasis	3.16e-05	0.000343	CcSEcCtD
Bosutinib—Nausea—Prednisone—psoriasis	3.13e-05	0.000339	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Beclomethasone—psoriasis	3.12e-05	0.00904	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Beclomethasone—psoriasis	3.12e-05	0.00904	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Fluocinonide—psoriasis	3.12e-05	0.00904	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Fluocinonide—psoriasis	3.12e-05	0.00904	CbGdCrCtD
Bosutinib—Pruritus—Methotrexate—psoriasis	3.11e-05	0.000338	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Fluocinolone Acetonide—psoriasis	3.03e-05	0.00879	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Fluocinolone Acetonide—psoriasis	3.03e-05	0.00879	CbGdCrCtD
Bosutinib—Diarrhoea—Methotrexate—psoriasis	3.01e-05	0.000327	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—psoriasis	2.91e-05	0.000316	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—psoriasis	2.8e-05	0.000304	CcSEcCtD
Bosutinib—Rash—Methotrexate—psoriasis	2.77e-05	0.000301	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—psoriasis	2.77e-05	0.000301	CcSEcCtD
Bosutinib—Headache—Methotrexate—psoriasis	2.76e-05	0.000299	CcSEcCtD
Bosutinib—Nausea—Methotrexate—psoriasis	2.61e-05	0.000284	CcSEcCtD
Bosutinib—PKMYT1—Danazol—Hydrocortisone—psoriasis	2.51e-05	0.00729	CbGdCrCtD
Bosutinib—CSNK1E—Danazol—Hydrocortisone—psoriasis	2.4e-05	0.00695	CbGdCrCtD
Bosutinib—PKMYT1—Danazol—Prednisone—psoriasis	2.16e-05	0.00627	CbGdCrCtD
Bosutinib—CSNK1E—Danazol—Prednisone—psoriasis	2.06e-05	0.00599	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Hydrocortisone—psoriasis	1.53e-05	0.00444	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Hydrocortisone—psoriasis	1.53e-05	0.00444	CbGdCrCtD
Bosutinib—CHEK2—Testosterone Propionate—Hydrocortisone—psoriasis	1.47e-05	0.00428	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Dexamethasone—psoriasis	1.42e-05	0.00412	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Betamethasone—psoriasis	1.42e-05	0.00412	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Triamcinolone—psoriasis	1.39e-05	0.00403	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Triamcinolone—psoriasis	1.39e-05	0.00403	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—psoriasis	1.32e-05	0.00382	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—psoriasis	1.32e-05	0.00382	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Prednisolone—psoriasis	1.29e-05	0.00373	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisolone—psoriasis	1.29e-05	0.00373	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Hydrocortisone—psoriasis	1.23e-05	0.00356	CbGdCrCtD
Bosutinib—CHEK2—Norethindrone—Hydrocortisone—psoriasis	1.1e-05	0.00321	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Prednisone—psoriasis	1.06e-05	0.00306	CbGdCrCtD
Bosutinib—CHEK2—Levonorgestrel—Hydrocortisone—psoriasis	8.79e-06	0.00255	CbGdCrCtD
Bosutinib—MAP3K7—Immune System—STAT3—psoriasis	1.69e-06	1.28e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—IL6—psoriasis	1.69e-06	1.27e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL6—psoriasis	1.69e-06	1.27e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—psoriasis	1.69e-06	1.27e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—APOE—psoriasis	1.68e-06	1.27e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—LEP—psoriasis	1.68e-06	1.27e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SOCS1—psoriasis	1.68e-06	1.27e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—IL6—psoriasis	1.68e-06	1.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—LEP—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—APOE—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—JUN—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—JUN—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—NFKB1—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—JUN—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IL6—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NFKBIA—psoriasis	1.67e-06	1.26e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TYK2—psoriasis	1.66e-06	1.25e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IL6—psoriasis	1.66e-06	1.25e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—CD4—psoriasis	1.66e-06	1.25e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—TYK2—psoriasis	1.65e-06	1.25e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS2—psoriasis	1.65e-06	1.24e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CD4—psoriasis	1.65e-06	1.24e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—NFKB1—psoriasis	1.65e-06	1.24e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL6—psoriasis	1.65e-06	1.24e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL6—psoriasis	1.64e-06	1.24e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—CXCL8—psoriasis	1.64e-06	1.23e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—JUN—psoriasis	1.63e-06	1.23e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—IL6—psoriasis	1.63e-06	1.23e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NFKBIA—psoriasis	1.63e-06	1.23e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—JUN—psoriasis	1.63e-06	1.23e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL6—psoriasis	1.61e-06	1.22e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—JUN—psoriasis	1.61e-06	1.22e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NFKB1—psoriasis	1.61e-06	1.21e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NFKB1—psoriasis	1.61e-06	1.21e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—JUN—psoriasis	1.61e-06	1.21e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IFNG—psoriasis	1.61e-06	1.21e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—NFKB1—psoriasis	1.61e-06	1.21e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—JUN—psoriasis	1.6e-06	1.21e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—VEGFA—psoriasis	1.6e-06	1.21e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NFKBIA—psoriasis	1.59e-06	1.2e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—TYK2—psoriasis	1.59e-06	1.19e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL6—psoriasis	1.58e-06	1.19e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL6—psoriasis	1.58e-06	1.19e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—STAT3—psoriasis	1.58e-06	1.19e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—IL6—psoriasis	1.58e-06	1.19e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—VEGFA—psoriasis	1.58e-06	1.19e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—NFKB1—psoriasis	1.57e-06	1.19e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NFKBIA—psoriasis	1.57e-06	1.18e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—NFKB1—psoriasis	1.57e-06	1.18e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TYK2—psoriasis	1.56e-06	1.18e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—STAT3—psoriasis	1.56e-06	1.18e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NFKBIA—psoriasis	1.56e-06	1.18e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NFKB1—psoriasis	1.55e-06	1.17e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD4—psoriasis	1.55e-06	1.17e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IFNG—psoriasis	1.55e-06	1.17e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—NFKB1—psoriasis	1.55e-06	1.17e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CXCL8—psoriasis	1.55e-06	1.16e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—NFKB1—psoriasis	1.54e-06	1.16e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL6—psoriasis	1.53e-06	1.15e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—TYK2—psoriasis	1.53e-06	1.15e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CXCL8—psoriasis	1.52e-06	1.15e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—VEGFA—psoriasis	1.52e-06	1.14e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—psoriasis	1.51e-06	1.14e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—STAT3—psoriasis	1.5e-06	1.13e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD4—psoriasis	1.5e-06	1.13e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—psoriasis	1.49e-06	1.13e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—STAT3—psoriasis	1.48e-06	1.12e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—TYK2—psoriasis	1.47e-06	1.1e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—VEGFA—psoriasis	1.46e-06	1.1e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—VEGFA—psoriasis	1.46e-06	1.1e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—LEP—psoriasis	1.45e-06	1.1e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—APOE—psoriasis	1.45e-06	1.1e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—STAT3—psoriasis	1.45e-06	1.09e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—STAT3—psoriasis	1.45e-06	1.09e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CXCL8—psoriasis	1.45e-06	1.09e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—STAT3—psoriasis	1.44e-06	1.09e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—psoriasis	1.44e-06	1.09e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—JUN—psoriasis	1.44e-06	1.08e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—CD4—psoriasis	1.43e-06	1.08e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—JUN—psoriasis	1.42e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—STAT3—psoriasis	1.41e-06	1.07e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—VEGFA—psoriasis	1.41e-06	1.06e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—STAT3—psoriasis	1.41e-06	1.06e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—APOE—psoriasis	1.4e-06	1.06e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—LEP—psoriasis	1.4e-06	1.06e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—psoriasis	1.4e-06	1.05e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—STAT3—psoriasis	1.4e-06	1.05e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—psoriasis	1.39e-06	1.05e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—psoriasis	1.39e-06	1.05e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—STAT3—psoriasis	1.39e-06	1.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—JUN—psoriasis	1.39e-06	1.05e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—psoriasis	1.39e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—STAT3—psoriasis	1.38e-06	1.04e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NFKB1—psoriasis	1.38e-06	1.04e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—CD4—psoriasis	1.38e-06	1.04e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IFNG—psoriasis	1.37e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TYK2—psoriasis	1.37e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—STAT3—psoriasis	1.37e-06	1.03e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NFKB1—psoriasis	1.36e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CXCL8—psoriasis	1.36e-06	1.03e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NFKBIA—psoriasis	1.36e-06	1.02e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—TYK2—psoriasis	1.35e-06	1.02e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—JUN—psoriasis	1.34e-06	1.01e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—psoriasis	1.34e-06	1.01e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—JUN—psoriasis	1.34e-06	1.01e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NFKB1—psoriasis	1.34e-06	1.01e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TYK2—psoriasis	1.33e-06	1e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—STAT3—psoriasis	1.33e-06	1e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD4—psoriasis	1.32e-06	9.99e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—psoriasis	1.32e-06	9.98e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NFKBIA—psoriasis	1.31e-06	9.84e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TYK2—psoriasis	1.31e-06	9.84e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NFKB1—psoriasis	1.29e-06	9.75e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—NFKB1—psoriasis	1.29e-06	9.72e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TYK2—psoriasis	1.29e-06	9.69e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—STAT3—psoriasis	1.28e-06	9.68e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—psoriasis	1.28e-06	9.65e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TYK2—psoriasis	1.28e-06	9.63e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—STAT3—psoriasis	1.28e-06	9.63e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—JUN—psoriasis	1.27e-06	9.54e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—psoriasis	1.26e-06	9.47e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—VEGFA—psoriasis	1.26e-06	9.46e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—STAT3—psoriasis	1.24e-06	9.37e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—LEP—psoriasis	1.24e-06	9.35e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—APOE—psoriasis	1.24e-06	9.35e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—VEGFA—psoriasis	1.24e-06	9.33e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—psoriasis	1.23e-06	9.27e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—STAT3—psoriasis	1.23e-06	9.24e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CD4—psoriasis	1.22e-06	9.22e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NFKB1—psoriasis	1.22e-06	9.18e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—psoriasis	1.21e-06	9.11e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—STAT3—psoriasis	1.2e-06	9.06e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—psoriasis	1.19e-06	8.98e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CXCL8—psoriasis	1.19e-06	8.96e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—JUN—psoriasis	1.19e-06	8.94e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—psoriasis	1.18e-06	8.91e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—psoriasis	1.17e-06	8.85e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—STAT3—psoriasis	1.16e-06	8.76e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CXCL8—psoriasis	1.16e-06	8.75e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—STAT3—psoriasis	1.16e-06	8.73e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NFKBIA—psoriasis	1.16e-06	8.72e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—psoriasis	1.15e-06	8.65e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NFKB1—psoriasis	1.14e-06	8.6e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL8—psoriasis	1.14e-06	8.57e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CARM1—psoriasis	1.13e-06	8.53e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—psoriasis	1.13e-06	8.52e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAT—psoriasis	1.13e-06	8.52e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL8—psoriasis	1.12e-06	8.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL8—psoriasis	1.11e-06	8.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TYK2—psoriasis	1.11e-06	8.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—STAT3—psoriasis	1.11e-06	8.37e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—psoriasis	1.11e-06	8.34e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—JUN—psoriasis	1.11e-06	8.33e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—psoriasis	1.11e-06	8.33e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—psoriasis	1.11e-06	8.33e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—psoriasis	1.11e-06	8.33e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—STAT3—psoriasis	1.09e-06	8.25e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—psoriasis	1.09e-06	8.22e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—JUN—psoriasis	1.08e-06	8.13e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TYK2—psoriasis	1.07e-06	8.06e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—STAT3—psoriasis	1.07e-06	8.06e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—psoriasis	1.07e-06	8.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NFKB1—psoriasis	1.06e-06	8.02e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—psoriasis	1.06e-06	7.98e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—JUN—psoriasis	1.06e-06	7.96e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—psoriasis	1.05e-06	7.92e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—JUN—psoriasis	1.04e-06	7.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NFKB1—psoriasis	1.04e-06	7.83e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—JUN—psoriasis	1.03e-06	7.8e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—psoriasis	1.03e-06	7.79e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—psoriasis	1.03e-06	7.73e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NFKB1—psoriasis	1.02e-06	7.67e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—psoriasis	1.01e-06	7.63e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—psoriasis	1.01e-06	7.63e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—psoriasis	1.01e-06	7.6e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NFKB1—psoriasis	1e-06	7.55e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NFKB1—psoriasis	9.96e-07	7.51e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—psoriasis	9.87e-07	7.44e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—psoriasis	9.83e-07	7.41e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—psoriasis	9.75e-07	7.35e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—psoriasis	9.72e-07	7.33e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—psoriasis	9.67e-07	7.29e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—psoriasis	9.67e-07	7.29e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—psoriasis	9.66e-07	7.28e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—psoriasis	9.57e-07	7.21e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—psoriasis	9.54e-07	7.19e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—psoriasis	9.48e-07	7.15e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TYK2—psoriasis	9.47e-07	7.14e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—psoriasis	9.47e-07	7.14e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—psoriasis	9.43e-07	7.11e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—psoriasis	9.35e-07	7.05e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—psoriasis	9.34e-07	7.04e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—psoriasis	9.32e-07	7.02e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—psoriasis	9.31e-07	7.02e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—psoriasis	9.23e-07	6.96e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—psoriasis	9.19e-07	6.93e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—psoriasis	9.14e-07	6.89e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—psoriasis	9.09e-07	6.85e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—psoriasis	9.04e-07	6.81e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—psoriasis	9e-07	6.78e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—psoriasis	8.99e-07	6.77e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—psoriasis	8.98e-07	6.76e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—psoriasis	8.95e-07	6.75e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—psoriasis	8.93e-07	6.73e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—psoriasis	8.87e-07	6.69e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOE—psoriasis	8.78e-07	6.62e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—psoriasis	8.68e-07	6.54e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—psoriasis	8.66e-07	6.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NFKB1—psoriasis	8.65e-07	6.52e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—psoriasis	8.56e-07	6.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—psoriasis	8.4e-07	6.33e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—psoriasis	8.35e-07	6.3e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NFKB1—psoriasis	8.34e-07	6.28e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—psoriasis	8.25e-07	6.22e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—psoriasis	8.12e-07	6.12e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—psoriasis	8.09e-07	6.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—psoriasis	7.85e-07	5.92e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—psoriasis	7.77e-07	5.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—psoriasis	7.75e-07	5.84e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—psoriasis	7.67e-07	5.78e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—psoriasis	7.65e-07	5.76e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—psoriasis	7.65e-07	5.76e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—psoriasis	7.57e-07	5.7e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—psoriasis	7.49e-07	5.65e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—psoriasis	7.47e-07	5.63e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NFKB1—psoriasis	7.38e-07	5.56e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—psoriasis	7.3e-07	5.5e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—psoriasis	7.17e-07	5.4e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—psoriasis	7.12e-07	5.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—psoriasis	6.97e-07	5.26e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAT—psoriasis	6.96e-07	5.25e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—psoriasis	6.87e-07	5.17e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—psoriasis	6.83e-07	5.15e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—psoriasis	6.7e-07	5.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—psoriasis	6.68e-07	5.04e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—psoriasis	6.63e-07	5e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—psoriasis	6.62e-07	4.99e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—psoriasis	6.52e-07	4.91e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—psoriasis	6.38e-07	4.81e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—psoriasis	6.29e-07	4.74e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—psoriasis	6.25e-07	4.71e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—psoriasis	5.93e-07	4.47e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—psoriasis	5.72e-07	4.31e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—psoriasis	5.43e-07	4.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOE—psoriasis	5.41e-07	4.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—psoriasis	5.23e-07	3.94e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—psoriasis	5.06e-07	3.81e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—psoriasis	4.71e-07	3.55e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—psoriasis	4.63e-07	3.49e-06	CbGpPWpGaD
